Cel-Sci Rg

Cel‑SCI Corp, a U.S. clinical‑stage biotech, has Multikine, a Phase‑III immunotherapy for head‑and‑neck cancer, and a patented LEAPS platform that targets infections, autoimmune disorders, and cancer. Its partnership with Saudi Arabian Pharma drives growth.

Headquarters: United States (USA)

Cel-Sci Rg Logo
Company Profile
Traded Instruments
+ Add Instrument 1
Symbol Name Type Exchange Currency ISIN Status Actions
CVM Cel-Sci Rg
Cap: 0.0B
EQUITY ASE USD US1508376076 Active
📈
Home Login